SHEET A-08 / TITLE BLOCK
About Legal Wolverine
An independent editorial project that reads the BPC-157 TB-500 record like a drafting sheet — the measured findings drawn solid, the gaps drawn dashed, the regulatory status kept in the title block.
What this site is
Legal Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature, and the public FDA regulatory record, on the BPC-157 TB-500 blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and publicly available regulatory documents.
The name carries a drafting-table conceit, and it is deliberate. We treat the Wolverine blend as what it actually is — a two-component assembly whose individual parts have measured records and whose joint does not. Established single-component findings are drawn as solid edges; the unproven combination and the missing human data are drawn dashed. The honesty is in the line-style, not buried in a caveat.
What "legal" means here
The word legal in this site's name is editorial framing, not a service we offer and not a legal opinion we provide. It marks the position this publisher takes relative to the literature: we keep the regulatory and access record — FDA approval status, the 503A Category 2 placement of both components, the scheduled PCAC review, and the WADA prohibition — as a specification block on the Wolverine legal status and 503A compounding page.
We do not offer legal advice, medical advice, treatment, consultation, or prescription services, and we do not sell or supply any substance. Everything here is general information about the published science and the public regulatory landscape. Where the regulatory record is unsettled — as it is, with both components under a scheduled 2026 FDA committee review — we say so plainly and never state an outcome as decided.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in the Wolverine blend references: the peer-reviewed component studies, the 2025-2026 systematic reviews, and the FDA sources. We do not present rodent results as human expectations, we do not present a fixed-ratio vial as a validated dose, and we do not present the marketed synergy as proven — because no controlled combination study exists.
Where the literature is strong, we say so: BPC-157's transected-Achilles tendon data and VEGFR2-Akt-eNOS angiogenesis are well characterized, and Thymosin Beta-4's migration and wound-healing activity is consolidated in review. Where it is thin or absent — human combination efficacy, combination safety, a defined synergy ratio — we mark the gap rather than paper over it. That is the whole editorial posture: a precise reading of a two-part record, drawn to scale.